(Q44453455)

3 December 2017

title

Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy (English)

1 reference

3 December 2017

1 reference

1 reference

C Lebrun

1

1 reference

3 December 2017

D Fontaine

2

1 reference

3 December 2017

V Bourg

3

1 reference

3 December 2017

A Ramaioli

4

1 reference

3 December 2017

S Chanalet

5

1 reference

3 December 2017

F Vandenbos

6

1 reference

3 December 2017

M Lonjon

7

1 reference

3 December 2017

F Fauchon

8

1 reference

3 December 2017

P Paquis

9

1 reference

3 December 2017

M Frenay

10

1 reference

3 December 2017

publication date

1 April 2007

1 reference

European Journal of Neurology

3 December 2017

published in

1 reference

3 December 2017

volume

14

1 reference

3 December 2017

issue

4

1 reference

3 December 2017

page(s)

391-398

1 reference

Long-term outcome of low-grade oligodendroglioma and mixed glioma.

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Long-term outcome of oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Successful chemotherapy for recurrent malignant oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Preferential loss of paternal 19q, but not 1p, alleles in oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Prognostic factors for survival in adult patients with cerebral low-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Treatment outcomes and prognostic factors of patients with supratentorial low-grade oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Treatment of low-grade oligodendroglial tumors without radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Up-front chemotherapy with fotemustine (F) / cisplatin (CDDP) / etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Suspected low-grade glioma: is deferring treatment safe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

The neurocognitive effects of radiation in adult low-grade glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Low-grade oligodendroglioma responds to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Phase II trial of temozolomide in patients with progressive low-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Continuous growth of mean tumor diameter in a subset of grade II gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.01675.X

10.1111/J.1468-1331.2007.01675.X

21 January 2018

Identifiers

DOI

1 reference

3 December 2017

1 reference